



**CERTIFICATE OF MAILING 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

10-10-2003

Date

Terrie Lindquist  
Terrie Lindquist

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Jingwu Z. Zhang et al.

Serial No.: 10/612,468

Filed: 07/02/2003

For: T CELL RECEPTOR CDR3 SEQUENCE  
AND METHODS FOR DETECTING AND  
TREATING RHEUMATOID ARTHRITIS

§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Docket No.: 057186.000003

Art Unit: Unknown

Examiner: Unknown

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are the following documents:

1. Information Disclosure Statement;
2. Our return postcard, which we would appreciate your date stamping and returning


to us upon receipt.

I hereby authorize the Commissioner for Patents to charge any additional fees that may be required or credit any overpayment to Bracewell & Patterson Deposit Account No. 50-0259 (Order No. 57186.3).

Date: \_\_\_\_\_

Oct. 10, 2003

Respectfully submitted,



J. Wendy Davis, Registration No. 46,393  
BRACEWELL & PATTERSON, L.L.P.  
P. O. Box 61389  
Houston, Texas 77208-1389  
Direct Phone: (713) 221-3301  
Direct Fax: (713) 222-3287  
ATTORNEY FOR APPLICANT



**CERTIFICATE OF MAILING 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date 10-10-2003

Terrie Lindquist  
Terrie Lindquist

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Jingwu Z. Zhang et al.

Serial No.: 10/612,468

Filed: 07/02/2003

For: T CELL RECEPTOR CDR3 SEQUENCE  
AND METHODS FOR DETECTING AND  
TREATING RHEUMATOID ARTHRITIS

§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Docket No.: 057186.000003

Art Unit: Unknown

Examiner: Unknown

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with Applicant's duty of candor and good faith in accordance with the provisions of 37 C.F.R. § 1.56, § 1.97, and § 1.98, Applicant files this Information Disclosure Statement and attached Form PTO-1449 listing references of which Applicant is aware.


This Information Disclosure Statement is being filed before issuance of the first Office Action and no fee is required. In the event any fee is required, the Commissioner is hereby authorized to charge Bracewell & Patterson Deposit Account No. 50-0259 (57186.3).

Respectfully submitted,

Date: Oct. 10, 2003

J. Wendy Davis

J. Wendy Davis, Registration No. 46,393  
BRACEWELL & PATTERSON, L.L.P.  
P. O. Box 61389  
Houston, Texas 77208-1389  
Direct Phone: (713) 221-3301  
Direct Fax: (713) 222-3287  
ATTORNEY FOR APPLICANT



Substitute FORM 158A/PTO PTO CLAIMS (10-01)		U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/612,468
				<b>Filing Date</b>	07/02/2003
				<b>First Named Inventor</b>	Jingwu Z. Zhang et al.
				<b>Group Art Unit</b>	Unknown
				<b>Examiner Name</b>	Unknown
<b>Sheet</b>	1	<b>of</b>	3	<b>Attorney Docket Number</b>	057186.000003

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document			Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Country Code	Number	Kind Code (if known)			

OTHER PRIOR ART		
Examiner Initials	Cite No.	Include Name of Author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.
		Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;15:903-911.
		Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 ;423:356-361.
		Kerian-Candon S, Combe B, Vincent R, Clot J, Pinet V, Eliaou JF. HLA-DRB1 gene transcripts in rheumatoid arthritis. Clin Exp Immunol 2001;124:142-149.
		MacGregor A, Oilier W, Thomson W, Jawaheer D, Silman A. HLA~DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995;22:1032-1036.
		Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, Bruce B. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002;46:2320-2329.
		Dolhain RJEM, van der Heiden AN, Ter haar NT, Breedveld FC, Miltenburg AM. Shift towards T lymphocytes with a T helper 1 cytokine profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 12:1961-1969.
		Bemer B, Akca D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry J Rheumatol 2000;27:1 128-1135.
		Davis LS, Cush JJ, Schultz-Koops H, Lipsky PE. Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4 poducing T helper-2 effector cells. Arthritis Res 2001;3:54-64.
		Goronzy JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, Weyand CM. Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis, J Clin Invest 1994;94:2068-2076.



		Goronzy JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, Weyand CM. Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis. <i>J Clin Invest</i> 1994;94:2068-2076.
		Gonzalez-Quintial R, Baccala R, Pope RM, Theofilopoulos AN. Identification of clonally expanded T cells in rheumatoid arthritis using a sequence enrichment nuclease assay. <i>J Clin Invest</i> 1996;97:1335-1343.
		Alam A, Lambert N, Lule H, Coppin H, Mazieres B, de Preval C, et al. Persistence of dominant T cell clones in synovial tissues during rheumatoid arthritis. <i>J Immunol</i> 1996; 156:3480-3485.
		Londei M, Savill CM, Verhoef A, Brennan F, Leech ZA, Duance V, et al. Persistence of collagen type IT-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. <i>Proc Nati Acad Sci USA</i> 1989;86:636-640.
		Pope RM, Pahiavani MA, LaCour E, Sambol S, Desai BY. Antigen specificity of rheumatoid synovial fluid lymphocytes. <i>Arthritis Rheum</i> 1989;32:1371-1380.
		Devereux D, O'Hehir RE, McGuire J, van Schooten WC, Lamb JR. HLA-DR4Dw4-restricted T cell recognition of self antigen(s) in the rheumatoid synovial compartment. <i>Int Immunol</i> 1991 ;3 :635-640.
		Res PC, Struijk L, Leow A, Daha MR, van den Elsen PC, Breedveld FC. Inflamed joints of patients with rheumatoid arthritis contain T cells that display in vitro proliferation to antigens present in autologous synovial fluid. Functional analysis on the basis of synovial-fluid-reactive T cell clones and lines. <i>Hum Immunol</i> 1994;40:291-298.
		Paliard X, West SF, Lafferty JA, Clements IR, Kappler JW, Marrack P, et al. Evidence for the effects of a superantigen in rheumatoid arthritis. <i>Science</i> 1991 ;253:325-329.
		Holoshitz J, Klajman A, Drucker I, Lapidot Z, Yaretzky A, Frenkel A, et al. T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage. <i>Lancet</i> 1986;2:305-309.
		Zagon G, Tumang JR, Li Y, Friedman SM, Crow MK. Increased frequency of V beta 17-positive I cells in patients with rheumatoid arthritis. <i>Arthritis Rheum</i> 1994;37:1431-1440.
		Alam A, Lule J, Coppin H, Lambert N, Mazieres B, De Preval C, et al. T-cell receptor variable region of the beta-chain gene use in peripheral blood and multiple synovial membranes during rheumatoid arthritis. <i>Hum Immunol</i> 1995;42:331-339.
		VanderBorghet A, Geusens P, Vandevyver C, Raus J, Stinissen P. Skewed T-cell receptor variable gene usage in the synovium of early and chronic rheumatoid arthritis patients and persistence of clonally expanded T cells in a chronic patient. <i>Rheumatology</i> 2000;39:1189-1201.
		Jenkins RN, Nikaein A, Zimmermann A, Meek K, Lipsky PE. T cell receptor V beta gene bias in rheumatoid arthritis. <i>J Clin Invest</i> 1993;92:2688-2701.
		Williams WV, Fang Q, Demarco D, VonFeldt J, Zurier RB, Weiner DB. Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. <i>J Clin Invest</i> 1992;90:326-333.
		Li Y, Sun GR, Tumang JR, Crow MK, Friedman SM. CDR3 sequence motifs shared by oligoclonal rheumatoid arthritis synovial T cells. Evidence for an antigen-driven response. <i>J Clin Invest</i> 1994;94:2525-2531.
		Mima T, Ohshima S, Sasi M, Nishioka K, Shimizu M, Murata N, et al. Dominant & shared T cell receptor beta chain variable regions of I cells inducing synovial hyperplasia in rheumatoid arthritis. <i>Biochem Biophys Res Commun</i> 1999;263:172-180.
		Davey MP, Burgoine GA, Woody CN. TCRB clonotypes are present in CD4+ T cell populations prepared directly from rheumatoid arthritis. <i>Hum Immunol</i> 1997;55: 11-21.
		Even J, Lim A, Puisieux I, Ferradini L, Dietrich PY, Toubert A, et al. T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumors and inflammatory diseases. <i>Res Immunol</i> 1995; 146:65-80.
		Tang J, Myracle AD, Allen S, Karita E, Musonda R, Fultz PN, et al. Novel alleles at the lymphotoxin alpha (LTalpha) locus mark extended HLA haplotypes in native Africans. <i>Hum Immunol</i> 2001 ;62:269-278.
		Nakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. <i>Cancer Res.</i> 2000;60:3281-289.



		Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, et al. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 1999;163:3530-3538.
		Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, et al. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta4, and Vbeta7 peptides. Arthritis Rheum 1998;41:1919-1929.
		Moreland LW, Heck LW Jr, Koopman WJ, Saway PA, Adamson IC, Fronek Z, et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 1996;23:1353-1362.

Examiner Signature		Date considered	
-----------------------	--	-----------------	--